Translational Periodontal Research Laboratory, UT Health San Antonio, San Antonio, TX, USA.
Department of Periodontics, UT Health San Antonio, 7703 Floyd Curl Dr. 7894, TX, 78229-3900, San Antonio, USA.
BMC Microbiol. 2022 Sep 2;22(1):212. doi: 10.1186/s12866-022-02617-8.
Bone loss and deformation due to damage caused by injury or recurrent invasive infections presents a major clinical obstacle. While bone substitute biomaterials promote osseous tissue regeneration, their application in sites complicated by microbial infections such as osteomyelitis, is limited. Bioactive glass biomaterials (Bioglass) have been shown to have efficient mechanisms of repairing the integrity of bone, while inhibiting growth of a range of bacterial strains. There are several commercially available bioactive glass compounds, each with a unique chemical composition. One compound in particular, S53P4, has demonstrated antimicrobial effects in previous studies but the antimicrobial activity of the parent compound 45S5 has not been investigated.
To assess whether antimicrobial activity is common among bioglass compounds, 45S5-the parent compound, was evaluated in comparison to S53P4 for antibacterial and antibiofilm effects against multiple strains of aerobic and anaerobic bacteria associated with various types of osteomyelitis. Experiments of antimicrobial effects in liquid cultures demonstrated that both compounds were antimicrobial against various microbial genera including S. gordonii, V. parvula, P. aeruginosa and MRSA; particles of the smallest size (32-125 µm) invariably showed the most robust antimicrobial capabilities. When employed against biofilms ecological biofilms grown on hydroxyapatite, 45S5 particles produced a stronger reduction in biofilm mass compared to S53P4 particles when considering small particle ranges.
We found that 45S5 seems to be as effective as S53P4 and possibly even more capable of limiting bacterial infections. The efficacy of bioactive glass was not limited to inhibition of planktonic growth, as it also extended to bacterial biofilms. The increased antibacterial activity of 45S5 compared to S53P4 is true for a variety of size ranges.
由于损伤或反复侵袭性感染造成的骨丢失和变形，这是一个主要的临床障碍。虽然骨替代生物材料促进了骨组织的再生，但它们在骨髓炎等微生物感染部位的应用受到限制。生物活性玻璃生物材料（Bioglass）已被证明具有修复骨完整性的有效机制，同时抑制多种细菌菌株的生长。有几种市售的生物活性玻璃化合物，每种都具有独特的化学成分。特别是一种化合物 S53P4，在之前的研究中已经表现出了抗菌作用，但尚未研究母体化合物 45S5 的抗菌活性。
为了评估生物活性玻璃化合物是否具有抗菌活性，我们评估了母体化合物 45S5 与 S53P4 相比，对与各种类型骨髓炎相关的需氧和厌氧细菌的抗菌和抗生物膜作用。在液体培养物中的抗菌效果实验表明，两种化合物对多种微生物属都具有抗菌作用，包括 S. gordonii、V. parvula、P. aeruginosa 和 MRSA；最小尺寸（32-125μm）的颗粒始终表现出最强大的抗菌能力。当用于抗生态生物膜时，与 S53P4 颗粒相比，45S5 颗粒在考虑小颗粒范围时，对羟基磷灰石上生长的生物膜质量产生了更强的减少。
我们发现 45S5 似乎与 S53P4 一样有效，甚至更有能力限制细菌感染。生物活性玻璃的功效不仅限于抑制浮游生长，因为它还扩展到细菌生物膜。与 S53P4 相比，45S5 的抗菌活性增加适用于多种尺寸范围。
